Novartis AG (NVSEF) Stock Price & Analysis
Novartis AG (NVSEF) — price $156.50 (-1.85%), as of the Nov 19, 2026 trading session; market cap $296B.
Educational signal · not a buy or sell recommendation · How to read this
Novartis AG · NVSEF · Healthcare · Drug Manufacturers - General
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered): Novartis spans innovative prescription medicines, generics, biosimilars, active ingredients and biotechnology manufacturing services rather than relying on a uniform drug portfolio. Its case rests on whether broad commercial reach and sustained research spending can keep expanding profit and cash generation while debt remains far above liquid resources.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $156.50 | |
| Change on the day | -1.85% | |
| 52-week range | $123.69–$171.29 | |
| Market capitalisation | $296B | — |
| Price / earnings (trailing) | 30.47 | |
| Shares traded on the day | 20 | |
| Beta (volatility vs the S&P 500) | 0.49 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Novartis AG (NVSEF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 8, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Novartis AG (NVSEF), and what does it report?
Short answer · as of
Novartis researches, develops, manufactures and commercializes medicines worldwide.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
Innovative Medicines serves patients and healthcare professionals across areas including neuroscience, immunology, cardiovascular, renal and metabolic disease, while Sandoz supplies generics, biosimilars, anti-infectives, active ingredients and manufacturing services to external partners.
What do the latest results show for Novartis AG (NVSEF)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $14.11B.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
Revenue, gross profit, operating profit, net income and diluted earnings all improved from the immediately preceding period, but remained below the comparable earlier period. The rebound therefore reached well beyond sales and appeared clearly in operating and net profit.
The latest earnings release cleared analyst expectations for revenue and earnings after a mixed sequence of beats and misses. On the annual view, revenue and net income advanced while research spending also increased, showing that recent profit growth did not require a retreat from development investment.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $14.11B | $1.17B | $0.61 (diluted) |
| Q2 FY2026 | $14.09B | $3.19B | $1.67 (diluted) |
| Q1 FY2026 | $12.86B | $3.09B | $1.62 (diluted) |
| Q4 FY2025 | $13.44B | $2.43B | $1.26 (diluted) |
What are the financial strengths and risks for Novartis AG (NVSEF)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
Operating cash flow stayed positive throughout the displayed run and comfortably exceeded capital expenditure in the latest period. Trailing margins and free-cash-flow yield reinforce the picture of a profitable, cash-generative pharmaceutical operation.
Debt substantially exceeds cash and investments, short-term coverage ratios remain below full coverage, and cash has fallen materially across the reported window despite a recent recovery. Weaker prescription demand would therefore meet substantial research and commercial spending alongside a meaningful debt burden, reducing room for error even while current cash generation remains strong.
What should you watch next at Novartis AG (NVSEF)?
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
At the next release, watch whether revenue and earnings clear consensus while operating profit and operating cash flow preserve their latest rebound. Cash also needs monitoring against debt: stabilization would strengthen the financial picture, while renewed erosion would make the leverage gap harder to dismiss.
Consensus assumes revenue and earnings continue rising across the forecast horizon. Stagnant sales, weaker profit conversion or heavier cash use would conflict with that trajectory; continued growth paired with resilient cash generation would support it.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
How is Novartis AG scored?
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
Novartis combines the economics of an innovative-medicine developer with activities more typical of a generic and biosimilar supplier. It also produces finished-dose medicines, active ingredients and intermediates for external partners and offers biotechnology manufacturing services, so consolidated revenue blends patented prescription products with broader pharmaceutical supply and service activity.
That operating breadth differs from a pure research-led drug developer and from a pure generic producer. The financial profile still carries the heavy research commitment and high margins associated with innovative pharmaceuticals, while the balance sheet adds leverage that a comparison based only on product breadth would miss.
| Company | Price | Market value | Score |
|---|---|---|---|
| $485.00 Nov 19, 2026 | $386B | — Model unavailable | |
| $189.90 Sep 25, 2026 | $294B | — Model unavailable | |
| $24.45 Nov 18, 2026 | $98.0B | — Model unavailable | |
| $24.44 Nov 19, 2026 | $23.8B | — Model unavailable | |
| $39.50 Nov 19, 2026 | $174B | — Model unavailable | |
| $137.78 Nov 18, 2026 | $340B | — 5-pillar · not comparable | |
| $443.89 Nov 18, 2026 | $240B | — 5-pillar · not comparable | |
| $168.98 Nov 18, 2026 | $210B | — 5-pillar · not comparable | |
| $286.01 Nov 18, 2026 | $506B | — 5-pillar · not comparable | |
| $28.06 Nov 18, 2026 | $160B | — 5-pillar · not comparable | |
| $272.70 Nov 18, 2026 | $656B | — 5-pillar · not comparable | |
| $58.34 Nov 19, 2026 | $119B | — 5-pillar · not comparable |
The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held NVSEF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported NVSEF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Novartis AG (NVSEF)?
NVSEF Healthcare Stock FAQ
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered); the full attribution is under Sources. The last question is answered from this page's own dated data, not from the research.
What does Novartis sell beyond Innovative Medicines?
Sandoz supplies generic and biosimilar medicines, anti-infectives, active ingredients and intermediates, while also providing biotechnology manufacturing services to external partners.
How does Sandoz change the way Novartis revenue should be read?
Consolidated revenue reflects more than advanced prescription medicines. It also includes finished-dose generics, biosimilars, pharmaceutical ingredients and manufacturing services, giving Novartis a broader demand base than a pure innovative-drug developer.
Does Novartis generate cash while funding its research base?
Operating cash flow remained positive across the displayed periods and exceeded capital expenditure, while annual research spending increased alongside revenue and net income. Cash generation is therefore substantial, although debt remains well above liquid resources.
What does the Alnylam inclisiran collaboration add to Novartis?
The agreement covers development, production and commercialization of inclisiran, extending Novartis through a partnered medicine rather than an internally controlled program alone.
What is the NVSEF stock price today?
The last price recorded for Novartis AG (NVSEF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 18 figures on this page — 1 from SEC filings and earnings calls, 16 from Financial Modeling Prep (FMP) and 1 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com